{"brief_title": "Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid", "brief_summary": "The purpose of this study is to assess bone mineral density in patients switching from an oral bisphosphonate to zoledronic acid, compared to those staying on the oral bisphosphonate.", "condition": ["Osteoporosis"], "intervention_type": ["Drug"], "intervention_name": ["zoledronic acid"], "criteria": "Inclusion Criteria: - Post-menopausal women between 45 and 79 years of age - Must be osteopenic/osteoporotic - Treatment with oral bisphosphonate for at least 1 year Exclusion Criteria: - Any woman of child bearing potential - Treatment with other bone active agents Other protocol-defined inclusion/exclusion criteria may apply.", "gender": "Female", "minimum_age": "45 Years", "maximum_age": "79 Years", "healthy_volunteers": "No", "keyword": "osteoporosis, osteopenia, post-menopausal, zoledronic acid", "mesh_term": ["Osteoporosis", "Zoledronic acid", "Diphosphonates"], "id": "NCT00097812"}